/AVTR
AVTR Stock - Avantor, Inc.
Healthcare|Medical - Instruments & SuppliesNYSE
$11.27+1.85%
+$0.20 (+1.85%) • Dec 19
53
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.16
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).63
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.83
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+6.5%upside
Target: $12.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AVTR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.16 – $11.38
TARGET (TP)$12.00
STOP LOSS$10.37
RISK/REWARD1:0.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.93
52W High$23.32
52W Low$10.62
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $6.78B | $6.97B | $7.51B | $7.39B | $6.39B |
| Gross Profit | $2.28B | $2.36B | $2.60B | $2.50B | $2.08B |
| Gross Margin | 33.6% | 33.9% | 34.6% | 33.9% | 32.5% |
| Operating Income | $1.08B | $696.40M | $1.13B | $972.20M | $706.80M |
| Net Income | $711.50M | $321.10M | $686.50M | $572.60M | $116.60M |
| Net Margin | 10.5% | 4.6% | 9.1% | 7.8% | 1.8% |
| EPS | $1.05 | $0.48 | $1.02 | $0.86 | $0.09 |
Company Overview
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
22%
Hold / Neutral
13
72%
Sell / Underperform
1
6%
Analyst Consensus🔴 Bearish
4 Bullish14 Neutral/Bearish
Price Targets
$21
Average Target
↑ 88.4% Upside
Now
$9
Low
$21
Average
$32
High
Based on 19 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 17th 2025 | Jefferies | Downgrade | Underperform | $9 |
| December 15th 2025 | BofA Securities | Downgrade | Neutral | $13 |
| November 4th 2025 | Raymond James | Downgrade | Market Perform | - |
| October 30th 2025 | Barclays | Downgrade | Equal Weight | $12 |
| October 30th 2025 | JP Morgan | Downgrade | Neutral | $12 |
| August 1st 2025 | Jefferies | Downgrade | Hold | - |
| April 29th 2025 | Goldman | Downgrade | Neutral | $14 |
| April 28th 2025 | TD Cowen | Downgrade | Hold | $15.5 |
| April 28th 2025 | Stifel | Downgrade | Hold | $14 |
| April 28th 2025 | Morgan Stanley | Downgrade | Equal Weight | - |
| January 17th 2025 | UBS | Downgrade | Neutral | $25← $29 |
| August 28th 2024 | Wells Fargo | Initiation | Overweight | $30 |
| July 10th 2024 | Citigroup | Downgrade | Neutral | $23← $30 |
| January 4th 2024 | Evercore ISI | Upgrade | Outperform | $26← $19.5 |
| December 11th 2023 | TD Cowen | Upgrade | Outperform | $28← $21 |
Earnings History & Surprises
AVTRBeat Rate
67%
Last 18 quarters
Avg Surprise
+4.6%
EPS vs Estimate
Beats / Misses
12/5
1 met exactly
Latest EPS
$0.22
Q4 2025
EPS Surprise History
Q1 24
+13.6%
$0.25vs$0.22
Q2 24
+9.5%
$0.22vs$0.20
Q3 24
+7.6%
$0.25vs$0.23
Q4 24
+2.1%
$0.26vs$0.25
Q1 25
+8.0%
$0.27vs$0.25
Q2 25
-0.6%
$0.23vs$0.23
Q3 25
-4.0%
$0.24vs$0.25
Q4 25
-4.3%
$0.22vs$0.23
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 23, 2026 | — | — | — | — |
Q1 2026 | Feb 6, 2026 | $0.21 | — | — | — |
Q4 2025 | Oct 29, 2025 | $0.23 | $0.22 | -4.3% | ✗ MISS |
Q3 2025 | Aug 1, 2025 | $0.25 | $0.24 | -4.0% | ✗ MISS |
Q2 2025 | Apr 25, 2025 | $0.23 | $0.23 | -0.6% | ✗ MISS |
Q1 2025 | Feb 7, 2025 | $0.25 | $0.27 | +8.0% | ✓ BEAT |
Q4 2024 | Oct 25, 2024 | $0.25 | $0.26 | +2.1% | ✓ BEAT |
Q3 2024 | Jul 26, 2024 | $0.23 | $0.25 | +7.6% | ✓ BEAT |
Q2 2024 | Apr 26, 2024 | $0.20 | $0.22 | +9.5% | ✓ BEAT |
Q1 2024 | Feb 14, 2024 | $0.22 | $0.25 | +13.6% | ✓ BEAT |
Q4 2023 | Oct 27, 2023 | $0.25 | $0.25 | 0.0% | = MET |
Q3 2023 | Jul 28, 2023 | $0.29 | $0.28 | -3.4% | ✗ MISS |
Q2 2023 | Apr 28, 2023 | $0.28 | $0.29 | +3.6% | ✓ BEAT |
Q1 2023 | Feb 3, 2023 | $0.30 | $0.32 | +6.7% | ✓ BEAT |
Q4 2022 | Oct 28, 2022 | $0.33 | $0.34 | +3.0% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $0.38 | $0.37 | -2.6% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | $0.35 | $0.38 | +8.6% | ✓ BEAT |
Q1 2022 | Feb 3, 2022 | $0.33 | $0.36 | +9.1% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $0.32 | $0.35 | +9.4% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $0.30 | $0.35 | +16.7% | ✓ BEAT |
Latest News
Jefferies Downgrades Avantor to Underperform, Lowers Price Target to $9
📉 NegativeBenzinga•Dec 17, 2025, 01:24 PM•Also:
Avantor Appoints Mary Blenn As Executive Vice President And COO, Effective Immediately
➖ NeutralBenzinga•Nov 10, 2025, 01:41 PM
Evercore ISI Group Maintains Outperform on Avantor, Lowers Price Target to $14
➖ NeutralBenzinga•Oct 30, 2025, 04:14 PM
Barclays Downgrades Avantor to Equal-Weight, Lowers Price Target to $12
📉 NegativeBenzinga•Oct 30, 2025, 01:01 PM•Also:
JP Morgan Downgrades Avantor to Neutral, Lowers Price Target to $12
📉 NegativeBenzinga•Oct 30, 2025, 12:44 PM
Avantor Lowers FY2025 Adj EPS Guidance from $0.94-$0.98 to $0.88-$0.92 vs $0.95 Est
📉 NegativeBenzinga•Oct 29, 2025, 02:08 PM
Avantor shares are trading lower after the company reported mixed Q3 results, missing EPS and revenue estimates.
📉 NegativeBenzinga•Oct 29, 2025, 10:45 AM
Avantor Unveils $500M Share Repurchase Plan, Underscoring Financial Strength And Focus On Long-Term Shareholder Returns
📈 PositiveBenzinga•Oct 29, 2025, 10:08 AM
Avantor Q3 Adj. EPS $0.22 Misses $0.23 Estimate, Sales $1.623B Miss $1.647B Estimate
📉 NegativeBenzinga•Oct 29, 2025, 10:06 AM
Baird Maintains Outperform on Avantor, Raises Price Target to $17
📈 PositiveBenzinga•Oct 24, 2025, 12:12 PM•Also:
Avantor Collaborates With P-Chip To Jointly Develop New Generation Of Smart Consumables
📈 PositiveBenzinga•Oct 23, 2025, 12:10 PM
Avantor shares are trading higher after Raymond James maintained an Outperform rating on the stock and raised its price target from $14 to $16.
📈 PositiveBenzinga•Oct 16, 2025, 05:28 PM
Raymond James Maintains Outperform on Avantor, Raises Price Target to $16
📈 PositiveBenzinga•Oct 16, 2025, 04:09 PM
Avantor Partners With BlueWhale Bio To Accelerate CAR-T Manufacturing With Next-Gen CDNP Platform
📈 PositiveBenzinga•Oct 15, 2025, 12:09 PM
Avantor Appoints Gregory L. Summe As Board Chairman, Effective Jan. 1, 2026, Succeeding Jonathan Peacock
➖ NeutralBenzinga•Oct 13, 2025, 08:06 PM
Avantor slides on revised outlook, revenue miss
📉 NegativeSeeking Alpha•Apr 25, 2025, 03:17 PM
Frequently Asked Questions about AVTR
What is AVTR's current stock price?
Avantor, Inc. (AVTR) is currently trading at $11.27 per share. The stock has moved +1.85% today.
What is the analyst price target for AVTR?
The average analyst price target for AVTR is $12.00, based on 1 analyst.
What sector is Avantor, Inc. in?
Avantor, Inc. operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NYSE exchange.
What is AVTR's market cap?
Avantor, Inc. has a market capitalization of $7.68 billion, making it a mid-cap company.
Does AVTR pay dividends?
No, Avantor, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATR
AptarGroup, Inc.
$121.39
Mkt Cap: $8.0B
BAX
Baxter International Inc.
$18.96
Mkt Cap: $9.7B
BIO
Bio-Rad Laboratories, Inc.
$301.53
Mkt Cap: $8.1B
GRFS
Grifols, S.A.
$9.02
Mkt Cap: $7.6B
HSIC
Henry Schein, Inc.
$77.35
Mkt Cap: $9.5B
MASI
Masimo Corporation
$134.04
Mkt Cap: $7.2B
MOH
Molina Healthcare, Inc.
$163.69
Mkt Cap: $8.9B
RGEN
Repligen Corporation
$162.38
Mkt Cap: $9.1B
STVN
Stevanato Group S.p.A.
$20.53
Mkt Cap: $5.6B
Explore stocks similar to AVTR for comparison